Mperia Therapeutics Appoints Paul Chipperton as President and CEO
November 9, 2018, Mperia’s Board of Directors announces today the appointment of Mr Paul Chipperton, as the new President and CEO, effective immediately. He will lead CD36 development programs in various chronic inflammation-based diseases such as dry age-related macular degeneration (dAMD), atherosclerosis and non-alcoholic steatohepatitis (NASH).
Paul is an award-winning serial life sciences entrepreneur, and comes with a proven track-record, most notably as 2008 co-founder and CEO of Profound Medical Inc., where in a 4-year span he raised more than $16M of venture capital financing, and the company subsequently went public in 2015, on the TSX Venture exchange (TSX:PRN, OTCQX:PRFMF). He currently sits on the boards of Intronix and Angel Investors Ontario. He is deeply experienced in rapidly transitioning academic research into established, well-financed clinical stage companies.
Paul commented, “I’m delighted to join Mperia Therapeutics. Dr Huy Ong, co-founder and Chief Scientific Officer is from the “old school” of R&D, and I found that very persuasive in this day and age. He is meticulous, precise and above all comprehensive in his research. Our data confirm we hold a unique advantage in both: (i) the understanding of the mechanism-of-action of CD36-mediated human biology, and (ii) a wealth of potent, patent-protected therapeutic compounds ready for advancement towards the clinic.”
“AmorChem is glad to welcome Paul Chipperton in Mperia’s team. With his outstanding business acumen, Paul will be key to position Mperia as the CD36 Therapeutics company which targets macrophages dysfunction to dampen chronic inflammation. He already counts on Veronique Bougie, Chief Operating Officer, for drug development and corporate affairs. Kevin McBride, partner at AmorChem, will also team up with Paul through his role on the Board. Kevin has long been involved in the CD36 story and he played a key role in the understanding of the breadth of opportunity offered by the biological function of CD36 and its importance to Mperia,” said Elizabeth Douville, co-founder and managing partner, AmorChem.
ABOUT MPERIA THERAPEUTICS
Mperia Therapeutics is the CD36 Therapeutics Company which focuses on macrophage-driven inflammation. The technology basis resides in highly specific CD36 receptor cyclic peptides which modulate the inflammasome in addition to modifying macrophages’ metabolic dysfunction with outstanding anti-inflammatory response. Mperia holds exclusive rights to various highly efficacious CD36 receptors ligands against dAMD and atherosclerosis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005193/en/